PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Buy PTC Therapeutics (PTCT) into the Kyndrisa Advisory Panel Tues - Oppenheimer
November 23, 2015 9:08 AM ESTOppenheimer analyst, Christopher Marai, anticipates a narrowly positive BioMarin (NASDAQ: BMRN) Kyndrisa panel outcome, and discussion highlighting key differentiation of PTC Therapeutics (NASDAQ: PTCT) data set, which would reflect positively on the Translarna package.
Key differences set Transarna's package above Kyndrisa... More
